BioAdaptives Inc.

BDPT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-1.6M $-899.2K $-712.5K $-895.6K $-1.0M $-847.2K $-238.9K $-1.4M
Depreciation & Amortization
Depreciation $4.0K $0
Amortization $0 $1.9K $28.2K $62.1K $133.8K
Stock-Based Compensation $28.7K $0 $163.9K $47.1K $0 $272.7K
Net Cash from Operating Activities $-516.0K $-249.5K $-223.8K $-227.3K $-158.7K $-106.9K $-168.1K $-420.1K
Investing Activities
Capital Expenditures $18.0K $0
Business Acquisitions
Net Cash from Investing Activities $-18.0K $0 $32.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $555.0K $326.2K $259.1K $169.7K $237.0K $99.2K $124.2K $426.0K
Net Change in Cash $-57.5K $78.3K $-7.7K
Free Cash Flow $-534.0K $-249.5K
← Newer Page 1 of 2 Older →